These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 9951495

  • 1. The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy.
    Shin DH, McCracken MS, Bendel RE, Pearlman R, Juzych MS, Hughes BA, Schulz LL, Kim C, Baek NH.
    Ophthalmology; 1999 Feb; 106(2):386-90. PubMed ID: 9951495
    [Abstract] [Full Text] [Related]

  • 2. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
    Bucci MG.
    J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
    [Abstract] [Full Text] [Related]

  • 3. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
    Denis P, Lafuma A, Khoshnood B, Mimaud V, Berdeaux G.
    Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
    [Abstract] [Full Text] [Related]

  • 4. A study of replacement of timolol-pilocarpine with latanoprost in pseudoexfoliation glaucoma.
    Bojić L, Mandić Z, Novak-Laus K, Sonicki Z, Karelović D.
    Coll Antropol; 2003 Dec; 27(2):729-34. PubMed ID: 14746165
    [Abstract] [Full Text] [Related]

  • 5. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
    Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE.
    Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
    [Abstract] [Full Text] [Related]

  • 6. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
    Maruyama K, Shirato S.
    J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013
    [Abstract] [Full Text] [Related]

  • 7. Latanoprost in glaucoma associated with Sturge-Weber syndrome: benefits and side-effects.
    Altuna JC, Greenfield DS, Wand M, Liebmann JM, Taglia DP, Kaufman PL, Cioffi GA, Lee DA, Robin AL, Crichton A, Costa VP, Ritch R.
    J Glaucoma; 1999 Jun; 8(3):199-203. PubMed ID: 10376261
    [Abstract] [Full Text] [Related]

  • 8. Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma.
    Gupta SK, Agarwal R, Galpalli ND, Srivastava S, Agrawal SS, Saxena R.
    Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):665-71. PubMed ID: 18200329
    [Abstract] [Full Text] [Related]

  • 9. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM, Bimatoprost Circadian IOP Study Group.
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of adjunctive mitomycin C during Ahmed Glaucoma Valve implantation: a prospective randomized clinical trial.
    Costa VP, Azuara-Blanco A, Netland PA, Lesk MR, Arcieri ES.
    Ophthalmology; 2004 Jun; 111(6):1071-6. PubMed ID: 15177955
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
    Shin DH, Feldman RM, Sheu WP, Fixed Combination Latanoprost/Timolol Study Group.
    Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
    [Abstract] [Full Text] [Related]

  • 12. Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension.
    Kent AR, Vroman DT, Thomas TJ, Hebert RL, Crosson CE.
    J Glaucoma; 1999 Aug; 8(4):257-62. PubMed ID: 10464735
    [Abstract] [Full Text] [Related]

  • 13. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K, Zimmerman TJ, Downes N, Schoenfelder J, Xalacom/Latanoprost Study Group.
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [Abstract] [Full Text] [Related]

  • 14. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.
    García-Feijoo J, Martínez-de-la-Casa JM, Castillo A, Méndez C, Fernández-Vidal A, García-Sánchez J.
    Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572
    [Abstract] [Full Text] [Related]

  • 15. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
    Tamer C, Oksüz H.
    Ophthalmic Res; 2007 Sep; 39(1):24-31. PubMed ID: 17164574
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Kałuzny J, Sobecki R, Czechowicz-Janicka K, Kecik D, Kałuzny BJ, Stewart JA, Stewart WC.
    Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of latanoprost additive therapy on uncontrolled glaucoma.
    Bayer A, Tas A, Sobaci G, Henderer JD.
    Ophthalmologica; 2002 Dec; 216(6):443-8. PubMed ID: 12566890
    [Abstract] [Full Text] [Related]

  • 18. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance Organization.
    Law SK, Song BJ, Fang E, Caprioli J.
    Ophthalmology; 2005 Dec; 112(12):2123-30. PubMed ID: 16225924
    [Abstract] [Full Text] [Related]

  • 19. Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle-closure glaucoma.
    Aung T, Chan YH, Chew PT, EXACT Study Group.
    Ophthalmology; 2005 Feb; 112(2):267-71. PubMed ID: 15691562
    [Abstract] [Full Text] [Related]

  • 20. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA, Renard JP, Cunliffe IA, Rojanapongpun P.
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.